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A novel coronavirus, SARS-CoV-2, has been identified as the causative agent of the current
COVID-19 pandemic. Animal models, and in particular non-human primates, are essential to
understand the pathogenesis of emerging diseases and to assess the safety and efficacy of novel
vaccines and therapeutics. Here, we show that SARS-CoV-2 replicates in the upper and lower
respiratory tract and causes pulmonary lesions in both rhesus and cynomolgus macaques.
Immune responses against SARS-CoV-2 are also similar in both species and equivalent to those
reported in milder infections and convalescent human patients. This finding is reiterated by our
transcriptional analysis of respiratory samples revealing the global response to infection. We
describe a new method for lung histopathology scoring that will provide a metric to enable
clearer decision making for this key endpoint. In contrast to prior publications, in which rhesus
are accepted to be the preferred study species, we provide convincing evidence that both
macaque species authentically represent mild to moderate forms of COVID-19 observed in the
majority of the human population and both species should be used to evaluate the safety and
efficacy of interventions against SARS-CoV-2. Importantly, accessing cynomolgus macaques will
greatly alleviate the pressures on current rhesus stocks.
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A novel acute respiratory syndrome, now called Cor-onavirus disease-19 (COVID-19) was first reported inChina in December 2019. The genetic sequence of the
causative agent was found to have similarity with two highly
pathogenic respiratory beta Coronaviruses, SARS-CoV-11 and
MERS2, and was later called SARS-CoV-23. It has currently
infected >57 million individuals resulting in >1.3 million deaths4.
Among the clinical and pathological signs of SARS-CoV-2
infection in humans, pneumonia accompanied by respiratory
distress seem to be the most clinically relevant5,6.
The development of animal models that replicate human dis-
ease is a crucial step in the study of pathogenesis and transmis-
sion, in addition to the assessment of the safety and efficacy of
candidate vaccines and therapeutics. Due to their obvious phy-
siological similarities to humans, non-human primates (NHPs),
such as macaques, have long been recognised as the most clini-
cally relevant animal for the development of in vivo models of
human disease. Prior NHP models developed for SARS-CoV-1
and MERS have shown respiratory induced pathology with
similar features as those seen in humans, including diffuse
alveolar damage. For SARS-CoV-1, though rhesus macaques
became the preferred species, yet the literature suggests there is
no significant difference in susceptibility of cynomolgus (Macaca
fascicularis) or rhesus macaques (Macaca mulatta) to infection,
virus replication and pathology7–10. Recent studies have shown
that rhesus macaques11,12 and cynomolgus macaques13 can be
infected by SARS-CoV-2 and the disease course resembles some
features of human COVID-19 infection. Rhesus macaques appear
to display more extensive lung pathology and clinical signs14;
however, a direct comparison of species, based on these studies, is
not possible because different strains of virus, dose and route of
administration have been used. A head-to-head comparison of
rhesus versus cynomolgus macaques, under the same experi-
mental conditions, is urgently required as there are now acute
pressures on rhesus stocks that will impact on the ability to
perform safety and efficacy studies on new vaccines and
therapeutics.
This unique study aims to evaluate the outcome of exposure to
SARS-CoV-2 in a head-to-head comparison of two macaque
species: rhesus macaque (Indian genotype) and cynomolgus
macaque (Mauritian genotype) exposed to the same well char-
acterised strain of challenge virus.
Similar to recent NHP studies, a dose of 5 × 106 pfu of SARS-
CoV-2/Victoria/01/202015, was delivered via the intranasal (IN)
and intratracheal (IT) route to groups of each species comprising
six animals. We perform sequential body fluid sampling and culls
(at days 4/5, 14/15 and 18/19) to support a comprehensive
comparative assessment of clinical signs, pathology, virology and
immunology. The results indicate parallel URT and LRT virus
replication, patterns of lung pathology and adaptive immunity.
This comparative data is reiterated in the global transcriptomics
response between the two species that closely resemble a mild to
moderate COVID-19 in humans.
Results
Clinical signs and in-life imaging by CT scan. Six rhesus
macaques of Indian genotype and six cynomolgus macaques of
Mauritian genotype were obtained from established UK Gov-
ernment breeding colonies (Fig. 1). Study groups comprised three
males and three females of each species and all were adults aged
two to four years with body weights ranging between 2.89 and
4.85 kg at time of challenge. Animals were challenged with a total
of 5 × 106 pfu of SARS-CoV-2/Victoria/01/2020 administered in
volumes of 2 ml by the intratracheal route (using a bronchoscope
for accurate placement right above the carinal bifurcation) and 1
ml by the intranasal route (0.5 ml in each nostril). Whole-genome
sequencing of the viral challenge stock, used in this study (Pas-
sage 3), confirmed there were no significant changes following
passage in Vero/hSLAM cells, compared to the original isolate
(Passage 1).
No significant weight loss or changes in body temperature were
observed throughout the experiment. Adverse clinical signs were
not recorded for any animal despite frequent monitoring during
the study period.
Images from CT scans collected 18 days after challenge from
two rhesus and two cynomolgus macaques, were examined by
an expert thoracic radiologist with prior experience of non-
human primate CT interpretation and human COVID-19 CT
features, blinded to the clinical status. Pulmonary abnormalities
that involved less than 25% of the lung and reflected those
characteristics of SARS-CoV-2 infection in humans, were
identified in one rhesus macaque and both cynomolgus
macaques (Fig. 2). Ground glass opacity was observed in all
three macaques showing abnormal lung structure, with
Fig. 1 Experimental study design. Rhesus and cynomolgus macaques were inoculated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) and culled in groups at three time points (4/5; 14/15 and 18/19 dpc). Animals were monitored for clinical signs and blood/swab/tissue samples were
taken for virology, immunology and pathology. CT scan imaging was carried out at 18 dpc.
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peripheral consolidation also seen in one cynomolgus macaque.
Abnormalities occurred in the peripheral two thirds of the
middle and lower lung lobes in the two cynomolgus macaques
and in a random pattern in the upper, middle and lower lobes
of the rhesus macaque. Pulmonary emboli were not identified in
any of the subjects.
Viral load in clinical samples. Viral load in the upper respiratory
tract (URT) (nasal washes and throat swabs), gastrointestinal
tract (rectal swabs) and in systemic samples (EDTA blood) was
assessed by CDC N-gene RT-qPCR and subgenomic E-gene RT-
qPCR at regular intervals throughout the study, and in bronch-
ioalveolar lavage (BAL) collected at necropsy (Fig. 3). High levels
of viral RNA (>106 cDNA copies/ml) were detected in nasal wash
samples collected from both species one day post-challenge (dpc).
In rhesus macaques, viral RNA in nasal washes peaked at 2 dpc at
6.9 ± 2.3 × 107 cDNA copies/ml and levels remained between 2.9
× 105 and 4.8 × 107 cDNA copies/ml until 11 dpc, before
decreasing to ≤1.8 × 104 cDNA copies/ml by 18 dpc. Cynomolgus
macaques displayed a similar pattern of viral RNA burden in
nasal wash samples with peak levels detected at 3 dpc. However,
levels later in infection remained higher with titres of 2.0 × 106
cDNA copies/ml at 15 dpc and 1.6 × 105 cDNA copies/ml at 19
dpc (Fig. 3a). These results were in line with the viral subgenomic
RNA (sgRNA) that was greatest for rhesus macaques at 2 dpc and
cynomolgus macaques at 3 dpc (Fig. 3b).
Viral load in throat swabs largely mirrored that in nasal washes
with peak levels early in infection, although, overall titres were
lower. This was most notable at 2 dpc (Fig. 3c). In rhesus
macaques, viral RNA was detected above the lower limit of
quantification (LLOQ—2.66 × 103 copies/ml) in all but one
animal between 1 and 3 dpc and remained ≥1.5 × 104 copies/ml
for all animals between 4 and 9 dpc before falling and remaining
below the assay’s lower limit of detection (LLOD) from 11 to 18
dpc. Throat swabs from cynomolgus macaques contained higher
levels of viral RNA early in infection (1–3 dpc) and remained ≥4.5
× 104 copies/ml for all animals between 4 and 9 dpc. The viral
subgenomic RNA (sgRNA) was highest for rhesus macaques at 1
and 3 dpc and for cynomolgus macaques at 1, 5 and 6 dpc
(Fig. 3d), which corresponded to the highest level of total viral
RNA detected.
Viral load in BAL samples echoed URT samples, with high
(≥9.8 × 106 copies/ml) levels in both species at 4 and 5 dpc,
dropping to ≤2.4 × 104 copies/ml and ≤1.9 × 104 copies/ml at 14
dpc and 15 dpc in rhesus and cynomolgus macaques, respectively
(Fig. 3e). These results were mirrored by the viral subgenomic
RNA with 1.7 × 105 copies/ml (sgRNA) at 5 dpc for rhesus and
4.8 × 104 copies/ml (sgRNA) at 4 dpc for cynomolgus macaques
(Fig. 3f).
Virus shedding from the gastrointestinal tract was assessed by
RT-qPCR performed on rectal swab samples. In rhesus macaques,
low levels of viral RNA were detected from 1 to 9 dpc. In
cynomolgus macaques, viral RNA was similarly detected at a low
level in rectal swabs from 1 to 9 dpc. However viral RNA levels
above the LLOQ were detected at both 3 and 5 dpc in cynomolgus
macaques in comparison to 2 and 3 dpc in rhesus macaques
(Fig. 3g).
Viral RNA was detected at only two timepoints after challenge
in whole blood samples, although below the LLOQ, and remained
below the LLOQ throughout the study (Fig. 3h). In rhesus
macaques, viral RNA was detected in one animal at 3 dpc, whilst
in cynomolgus macaques, viral RNA was detected in two animals
at 6 dpc.
Viral RNA was detected in the nasal cavity, lung and trachea
early in infection at 4 and 5 dpc. Subgenomic RNA was also
detected in the nasal cavity of cynomolgus macaques at four and 5
dpc. In contrast, subgenomic RNA was detected above LLOQ for
rhesus at 4 and 5 dpc, and only at 5 dpc for cynomolgus
macaques. Tonsil samples were all below the LLOQ for all
timepoints. (Supplementary Fig. 1).
Samples collected from the upper respiratory tract at each
study time point were evaluated using a Vero cell-based plaque
assay for the presence of viable virus. Viable virus was successfully
recovered from two of the six rhesus macaques and three of
the six cynomolgus macaques on the first occasion of sampling
(1–3 dpc). In all cases, recovery was below 100 pfu/mL based on a
figure of under 10 plaques in a single well. Virus was not
recovered from any nasal wash samples collected from 4 dpc
onwards.
Pathological changes. Gross pathological changes were found in
the lungs of all animals from both species and sexes euthanised 4/
5 days after challenge and comprised multiple areas of mild to
moderate consolidation distributed in cranial and caudal lobes
(Supplementary Fig. 2). At 14/15 and 18/19 dpc, only small areas
of consolidation were observed. Macroscopic changes, considered
to be associated with infection, were not observed in any other







Fig. 2 CTscan images from cynomolgus and rhesus macaques infected
with SARS-CoV-2 and culled at 18 days post challenge. Images
constructed from CT scans collected 18 days after challenge with SARS-
CoV-2 showing pulmonary abnormalities in two cynomolgus (a, b) and one
rhesus macaque (c). Arrows in images (a1), (b1) and (c1) indicate areas of
peripheral ground glass opacification. Arrows in images (a2) and (c2)
indicate areas of ground glass opacification and arrow in image (b2)
indicates an area of consolidation. Images from a second rhesus macaque
did not have abnormal features.
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Histological changes in the lungs of all twelve animals from
both species, consistent with infection with SARS-CoV-2, were
observed. The changes were most prominent at 4/5 dpc and
thereafter were less severe, indicating resolution of the more acute
changes observed at early time points.
Four and five days after challenge, the lung parenchyma in the
cynomolgus macaques was comprised of multifocal to coalescing
areas of pneumonia, surrounded by unaffected parenchyma.
Overall, alveolar necrosis was a prominent feature in the affected

































































































































































































































































Fig. 3 Viral RNA detected by RT-qPCR. Viral load presented as the geometric mean of RNA copies/mL or individual values, with individual data points
overlaid in rhesus macaques (blue) and cynomolgus macaques (red) in (a) nasal wash total RNA, (b) nasal wash Sg RNA, (c) throat swab total RNA, (d)
throat swab Sg RNA (e) bronchoalveolar lavage (BAL) total RNA, (f) bronchoalveolar lavage (BAL) Sg RNA (numbers indicate days post-challenge the
NHP was euthanised), (g) rectal swab total RNA, (h) whole blood total RNA. n= 2 macaques per group/species at 1, 2, 3, 6, 8, 9, 11, 12, 14, 15, 18 and 19
dpc; n= 1 at 4 dpc; n= 3 at 5 dpc (for BAL; n= 1 at 4 and 5 dpc and n= 2 at 14,15, 18 and 19 dpc). Bars show median values. Dashed lines highlight the
LLOQ (lower limit of quantification, 8.57 × 103 copies/mL for total RNA and 1.29 × 104 copies/mL subgenomic RNA) and LLOD (lower limit of detection,
2.66 × 103 copies/mL for total RNA, 1.16 × 103 copies/mL for subgenomic RNA). Positive samples detected below the LLOQ were assigned the value of
5.57 × 103 copies/mL for total RNA and 12.86 × 104 copies/mL subgenomic RNA. Viral RNA was not detected in naïve animals. Samples for RT-qPCR and
sgPCR were assayed in duplicate against a standard curve in triplicate.
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alveolar walls, with pyknotic or karyorrhectic nuclei (Fig. 4a). In
these areas, alveolar spaces were often obliterated by collapse of
the thickened and damaged alveolar walls which contained mixed
inflammatory cells (Fig. 4a,b); or had obvious, alveolar type II
pneumocyte hyperplasia (alveolar epithelialisation), as well as
expanded alveolar spaces (Fig. 4b). Alveolar spaces were
expanded and filled with fibrillar to homogenous, eosinophilic,
proteinaceous fluid (alveolar oedema) (Fig. 3a), admixed with
fibrin, neutrophils, enlarged alveolar macrophages, few lympho-
cytes and detached type II pneumocytes. In distal bronchioles,
degeneration and sloughing of epithelial cells were present, with
areas of attenuation; in alveolar walls associated with bronchiolo-
alveolar junctions, foci of plump, type II pneumocytes were
noted, representing regeneration.
In the larger airways occasional, focal, epithelial degeneration
and sloughing were observed in the bronchial epithelium, with
evidence of regeneration, characterised by small, basophilic
epithelial cells. Low numbers of mixed inflammatory cells,
comprising neutrophils, lymphoid cells, and occasional eosino-
phils, infiltrated bronchial and bronchiolar walls. In the lumen of
some airways, mucus admixed with degenerative cells, mainly
neutrophils and epithelial cells, was seen. Occasionally, multi-
nucleated cells, characterised as large, irregularly shaped cells with
prominent, eosinophilic cytoplasm and multiple round nuclei
were observed (Fig. 4b, insert).
Pathological changes consistent with those described for
cynomolgus macaques were present in the lungs of rhesus
macaques. In the parenchyma, multifocal expansion and infiltra-
tion of alveolar walls by inflammatory cells were noted (Fig. 4c).
Furthermore, in these areas, alveolar necrosis was observed with
patchy alveolar oedema and accumulations of alveolar macro-
phages (Fig. 4c). In the bronchi and bronchioles, similar changes
to those described for cynomolgus macaques were seen (Fig. 4d).
Changes were less severe in all four animals examined at 14/15
dpc. In the cynomolgus macaques, patchy infiltration of mainly
mononuclear cells in the alveolar walls, with occasional similar
cells within alveolar spaces, and parenchymal collapse, were seen
(Fig. 4e). Mononuclear cells, primarily lymphocytes were also
noted surrounding and infiltrating the walls of blood vessels
(Fig. 4f) and airways. Furthermore, there was an increased
prominence of bronchial-associated lymphoid tissue (BALT) was
noted. In the lungs of rhesus macaques, changes in the alveoli and
BALT were similar in appearance and frequency to those
described in the cynomolgus macaques, and perivascular
lymphocytic cuffing of small vessels, characterised by concentric
infiltrates of mononuclear cells, was also seen occasionally
(Figs. 4g and 4h). By day 18/19, the changes were similar but
less frequent to those described at day 14/15 in all four animals.
Using the subjective histopathology scoring system, scores were
higher in both macaque species at 4/5 dpc compared to 14/15 and
18/19 dpc, mostly due to higher scores in the alveolar damage
parameters observed at the early time point (Fig. 5).
The presence of viral RNA was observed in the lungs from all
animals at 4/5 dpc by in situ hybridisation (ISH). Prominent
staining of small foci of cells containing SARS-CoV-2 viral RNA,
was observed within pneumocytes and interalveolar septa,
concomitant with microscopic changes in cynomolgus macaques
(Fig. 6a). Staining was not seen in cells or fluid within the alveolar
spaces. Positive mononuclear cells were also observed rarely in
the bronchus-associated lymphoid tissue (BALT) (Fig. 6a, insert).
Small foci of cells staining positive for viral RNA were observed at
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Fig. 4 Histopathological changes in cynomolgus and rhesus macaques during SARS-CoV-2 infection. Areas of alveolar necrosis observed in cynomolgus
macaques at 4/5 dpc with shrunken, eosinophilic cells within the alveolar walls (a, b), together with alveolar oedema (a, arrows; bar= 100 µm), type II
pneumocyte hyperplasia and expanded alveolar spaces with inflammatory cell infiltration (b, arrows; bar= 100 µm). Occasional multinucleated cells
are observed (b, insert; bar= 20 µm). Similar histopathological changes observed in rhesus macaques, including alveolar necrosis and areas with
patchy alveolar oedema (c, arrow; bar= 100 µm), and accumulatios of alveolar macrophages (d, arrow; bar= 100 µm) and bronchial exudates (d, insert;
bar= 50 µm). Histopathological changes with less severity observed at 14/15 dpc in cynomolgus macaques, with infiltration of mononuclear cells within
alveolar spaces and bronchiolar lumen (e, arrows; bar= 100 µm) and perivascular cuffing (f, arrow; bar= 100 µm). Bronchiole regeneration (g, arrow;
bar= 100 µm) and perivascular/peribronchiolar cuffing observed in rhesus macaques at 14/15 dpc (h, arrows; bar= 100 µm), together with BALT
proliferation (h, *; bar= 100 µm). Representative images from 6 slides per animal at each time point.


















Fig. 5 Lung histopathology scores. Heatmap showing the scores for
each lung pathology parameter and the average score for each animal
culled at 4/5, 14/15 and 18/19 dpc. Severity ranges from 0 to 4: 0= none;
1=minimal; 2=mild; 3=moderate and 4=marked/severe.
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and interalveolar septa of both animals at 4/5 dpc, concomitant
with microscopic changes (Fig. 6b).
Viral RNA was detected in only a few individual cells in both
groups of animals at 14/15 dpc (Figs. 6c, d). By day 18/19, viral
RNA was not detected by ISH. Overall, there was a high presence
of viral RNA at 4/5 dpc which was more pronounced in the
cynomolgus macaques; by contrast, only very few positive cells
were observed at 14/15 dpc and none at 18/19 dpc. (Fig. 6e).
Viral RNA was observed in scattered epithelial cells in areas of
the upper respiratory tract (nasal cavity, larynx and trachea) of all
animals at 4/5 dpc, and not associated with lesions.
Abundant numbers of cells expressing IL-6 mRNA were
observed within the pulmonary lesions, with only few positive
scattered cells in the healthy parenchyma.
IL-6 mRNA was abundant within the lesions in cynomolgus
(Fig. 6f) and rhesus macaques (Fig. 6g) at 4/5 dpc, which was
slightly more pronounced in cynomolgus macaques (Fig. 6j). The
expression of IL-6 mRNA was less pronounced in both
cynomolgus (Fig. 6h) and rhesus macaques (Fig. 6i) at 14/15
dpc, with no significant expression observed at 18/19 dpc.
In the liver, microvesicular, centrilobular vacuolation, consis-
tent with glycogen, together with, small, random, foci of
lymphoplasmacytic cell infiltration were noted rarely. This is
considered to represent a mild, frequently observed background
lesion. Remarkable changes were not observed in any other tissue.
Viral RNA staining was seen only at 4/5 dpc, in occasional,
absorbing epithelial and goblet cells in the small and large
intestine. It was not observed in any other tissue examined.
Antibody responses to SARS-CoV-2 infection. Low levels of
neutralising antibody were detected by plaque reduction neu-
tralisation test (PRNT) assay in both cynomolgus and rhesus
macaques for the first 8–9 days post-challenge. From day eleven
or twelve, both species showed high neutralising antibody titres
which continued at the later time point (14–19 dpc). The neu-
tralisation titres at the later time points were generally higher in
the cynomolgus macaques, although greater variability in titres
between different animals was seen for this species (Fig. 7).
Seroconversion to viral antigens Spike trimer, Receptor
Binding Domain (RBD) and Nucleoprotein were evaluated



















































Fig. 6 Presence of viral RNA and IL-6 by ISH in cynomolgus and rhesus macaques during SARS-CoV-2 infection. ISH detection of abundant viral RNA
(RNAScope, red chromogen) within the areas of pneumonia (a, arrows) and occasionally in the BALT (a, insert, arrow) in cynomolgus (a, b) and rhesus
macaques (b, arrows) at 4/5 dpc. Small amount of viral RNA in the interalveolar septa from cynomolgus (c, arrows) and rhesus macaques (d, arrows) at
14/15 dpc. Image analysis of positively stained area in RNASCope labelled sections for viral RNA (e, whole slide); n= 2 macaques per species and time
point; bars represent median values. Abundant presence of IL-6 mRNA in the areas of pneumonia from cynomolgus (f, arrows) and rhesus macaques (g,
arrows) at 4/5 dpc. Small amount of IL-6 mRNA positive cells within the interalveolar septa from cynomolgus (h, arrows) and rhesus macaques (i, arrows)
at 14/15 dpc. Image analysis of positively stained area in RNASCope labelled sections for IL-6 mRNA (j, areas of lesion); n= 2 macaques per species and
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Fig. 7 Neutralising antibodies in serum measured by Plaque reduction
neutralisation test (PRNT50). Serum neutralisation titres as reciprocal
highest dilution resulting in an infection reduction of >50% in samples
(PRNT50) pre-challenge and at 1–3, 4–6, 8–9, 11–12 and 14–19 days post-
challenge in rhesus macaques (blue) and cynomolgus macaques (red). For
rhesus macaques: n= 6 at 0, 1-3 and 4–6 dpc; n= 4 at 8-9 and 14-19 dpc;
n= 3 at 11–12 dpc. For cynomolgus macaques: n= 6 at 4–6 dpc; n= 5 at 0
and 1–3 dpc; n= 4 at 8–9; 11–12 and 14–19 dpc. Bars indicating group mean
±standard error with PRNT50 determined for individual animals shown as
circles and squares respectively. Neutralising antibodies were observed at
8–9 dpc at low levels, increasing from 11 dpc onwards, with higher values in
cynomolgus macaques compared to rhesus.
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SARS-CoV-2 were detected in serum collected from both rhesus
and cynomolgus macaques from 8 to 9 dpc onwards (Fig. 8).
Frequency of antigen-specific IFN-γ secreting cells measured
by ELISpot. Cellular immune responses induced by SARS-CoV-2
challenge were measured in peripheral blood mononuclear cells
(PBMCs) using an ex vivo IFN-γ ELISpot assay and compared to
responses measured in uninfected (naïve) age and species mat-
ched control animals (Fig. 9). Interrogation of IFN-γ spot
forming units (SFU) measured in response to stimulation with
overlapping 15-mer spike protein-peptide pools indicated that
peptides spanning the breadth of the SARS-CoV-2 spike protein
sequence induced cellular immune responses in infected cyno-
molgus macaques; whereas, peptide pool (PP) sequences 2-4 and
8 were most immunogenic in rhesus macaques (Fig. 9a, b).
In rhesus macaques, the IFN-γ SFU measured following
stimulation with spike protein peptide megapools (MP) 1–3 did
not differ significantly between animals euthanised at either the
day 4–5 (early) or the day 14–19 (late) post-infection time-point
in comparison to SFU frequencies measured in the naïve control
animals. However, comparison of the summed MP 1–3-specific
response indicated that significantly higher SFU frequencies were
present in the animals euthanised at the later time-point (P=
0.01) (Fig. 9c). By contrast, spike protein MP1-, MP2, and
summed MP-specific responses measured in cynomolgus maca-
ques were all significantly higher than in naïve control animals at
the later post-infection time-point (p= 0.03, p= 0.01, p= 0.01)
(Fig. 9d).
In general, there was a trend for spike protein peptide-specific
IFN-γ SFU frequencies measured in PBMC samples collected
from cynomolgus macaques to be greater than those detected in
rhesus macaques, although these differences did not reach
statistical significance.
Spike peptide-specific IFN-γ SFU frequencies measured in
mononuclear cells isolated from lung and spleen samples revealed
a trend for local cellular immune responses to be greatest in the
animals euthanised at the day 14 to19 post-infection time point,
but also that there was substantial variability within the groups at
this stage of infection (Fig. 9e).
Composition and functional profile of the cell-mediated immune
response. To explore changes in the composition of the cellular
immune compartment following SARS-CoV-2 infection, immu-
nophenotyping flow cytometry assays were applied to PBMCs
and lung mononuclear cells (MNC) samples collected at necropsy
and from PBMCs collected from age and species matched unin-
fected (naïve) animals. Comparison of CD4+ and CD8+ T-cell
frequencies indicated that the proportion of CD8+ T-cells was
greater in cynomolgus macaques prior to, and also after infection
when the frequency of the CD4+ subset increased but remained
secondary to the CD8+ population in peripheral blood and lung
MNC (Fig. 9f). Similarly, the frequency of γδ T-cells in peripheral
blood was higher in cynomolgus macaques but remained con-
sistent following infection, whereas γδ T-cell frequencies
appeared more variable in the lung MNC samples collected from
animals euthanised at the early and late post-infection time point
(Fig. 9g, h). Monocyte subtypes were characterised as classical,
non-classical or intermediate by expression of CD14+ and
CD16+. This revealed an increased frequency of ‘transitional’
CD14+ CD16+ and ‘non-classical’ CD14− CD16+ monocyte
subsets in PBMCs collected at the later post-infection time point
in both rhesus and cynomolgus species. In contrast, the immu-
nomodulatory non-classical monocyte population was more
abundant in lung tissue samples collected from rhesus macaques
euthanised early after infection in comparison to the later time
points or to cynomolgus macaques (Fig. 9i). Cytotoxic and
immunomodulatory natural killer (NK) cell populations were
identified within the CD3−, CD159a+ lymphocyte population
based on the expression on CD16 and CD56, respectively.
Immunomodulatory (CD56+) NK cell populations were detected
at higher frequency in the lung and PBMC of infected macaques










































































































































































Fig. 8 SARS-CoV-2-specific IgG antibodies measured by ELISA in naïve and SARS-CoV-2 infected macaques. Spike- (a), Receptor-Binding Domain- (b)
and Nucleoprotein- (c) specific IgG antibodies measured in sera of rhesus and cynomolgus macaques. Sera were collected from uninfected animals (day 0)
or 1–3, 4–6, 8–9, 11–12 and 14–19 days following SARS-CoV-2 infection. n= 6 at 0, 1–3 and 4–6 dpc; n= 4 at 8–9, 11–12 and 14 dpc. Bars show the group
mean±SEM with an endpoint titre determined for each individual animal shown as squares for males and dots for females. *p≤ 0.05 (Kruskal–Wallis one-
way ANOVA, two-sided). Experiment performed in duplicates.
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in comparison to naïve control animals, indicating a potential
proinflammatory role for this innate lymphoid cell subset in
SARS-CoV-2 infection (Fig. 9j).
To explore the functional profile of T-cell populations, PBMCs
were stimulated with peptide pools spanning the SARS-CoV-2
membrane (M), nucleocapsid (N) or spike (S) proteins, and the
production of the cytokines IFN-γ, IL-2, TNF-α, IL-17 and GM-
CSF along with the activation marker CD69 and degranulation
marker CD107a measured by intracellular cytokine staining.
Cytokine-producing CD4 and CD8 T-cells were detected in both
rhesus and cynomolgus macaques in response to stimulation with
M, N and S peptide pools. Proinflammatory (IFN-γ or GM-CSF
producing) T-cells were primarily detected at the later post-
challenge time point, although low frequencies of IL-2 producing
CD8+ cells were detected in PBMC samples collected from
cynomolgus macaques in the early post-challenge samples
(Fig. 9k). The frequency of Th17 and TNF-α expressing cells
differed between the species with IL-17 producing CD4 and CD8
T-cells more prevalent in rhesus macaques, whereas TNFα
expression was detected more frequently in cynomolgus maca-
ques. Similarly, cytokine production measured in the γδ T-cell
population indicated a trend for greater IL-17 production in
PBMCs isolated from rhesus macaques, although low frequencies
of IFN-γ and IL-17 producing γδ T-cells were also detected in
cynomolgus macaques euthanised at the early post-infection time
point indicating that unconventional T-cell populations play a
role in the early immune response to SARS-CoV-2 infection
(Fig. 9l). Peptide-specific expression of the degranulation marker
CD107a was assessed as a measure of cell mediated cytotoxicity.
CD107a was detected on CD8 and γδ T-cells in both rhesus and
cynomolgus macaques, was most potently induced by stimulation
with the M protein peptide pool and detected at higher frequency
in cynomolgus macaques at the early post-infection time points
(Fig. 9m, n). In addition to the above functional parameters,
antigen-specific expression of the activation marker CD69 was
assessed to provide a measure of the overall activation status and
SARS-CoV-2 antigen-reactogenicity of T-cell subsets following
infection. In general, CD69 expression on CD4, CD8 and γδ T-
cell populations was higher at the later post-infection timepoints
(Fig. 9k-l) and expression levels agreed with the detection of
cytokine production in the corresponding T-cell subsets. How-


















































































































































































































































































































Fig. 9 Cellular immune responses to SARS-CoV-2. a, b IFNγ SFU measured in PBMCs and stimulated with spike protein peptide pools (PP) peptide in (a)
rhesus and (b) cynomolgus macaques. PBMC samples were isolated from uninfected animals (naïve) or at early (days 4 and 5) and late (days 14-19) time-
points following SARS-CoV-2 infection. Box plots show the group median+ /− inter-quartile range, with minimum and maximum values connected by
whiskers. Two-tailed Mann–Whitney U-test carried out to compare pre and post-SARS-Cov2 infection where *p≤ 0.05, **p≤ 0.01. c, d IFNγ SFU measured
in PBMC in response to spike protein megapools (MP) in (c) rhesus and (d) cynomolgus macaques or, (e) in mononuclear cells isolated from lung and
spleen. Bars show the group median with SFU measured in individual animals shown as dots. Rhesus macaques summed MP naïve vs late time point p=
0.01. Cynomolgus macaques naïve vs PP9 p= 0.03, naïve vs MP2 p= 0.03, naïve vs MP3 p= 0.01, naïve vs summed p= 0.01. Biologically independent
animal samples for (a–d); PBMCs: naïve n= 6, early n= 2, late n= 4 Biologically independent animal samples for (e); lung and spleen: early n= 2, late n=
4, (f–j) Frequency of major lymphocyte and monocyte cell populations quantified by immunophenotyping assay (f–h) CD4+, CD8+ and γδ T-cell
frequencies in PBMCs and lung cells, (i) Monocyte subtype frequency in PBMCs and lung MNCs, (j) Natural killer (NK) cell subset frequency in PBMCs
and lung MNCs. Stacked bars show the group median with 95% confidence intervals. Biologically independent animal samples for (f–j); PBMC: Naïve
rhesus n= 8, early rhesus n= 1, late rhesus n= 2, naïve cyno = 7, early cyno n= 2, late cyno n= 2. Lung: early rhesus n= 2, late rhesus n= 3, early cyno
n= 2, late cyno n= 2. k–n Intracellular cytokine staining data. k–l Cytokine and activation marker detection in CD4+, CD8+and γδ T-cells in PBMCs
stimulated with M, N and S peptide pools. m–n CD107a expression in CD8+ and γδ T-cells in PBMCs. Bars show the group median with cell frequencies
measured in individual animals shown as dots.
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and S peptide stimulated samples, in which there was an absence
of cytokine or degranulation marker detection, indicating that
these activated cells may have exerted antigen-specific functions
outside of the parameters measured by our ICS assay.
Gene expression and gene network comparison of the host
response to SARS-CoV-2. Gene expression analysis by defining
mRNA profiles in clinical samples can be used to characterise the
host response to infection. For example, this approach has been
used to analyse blood samples to differentiate patients with acute
Ebola virus disease who went on to survive or die16 or to char-
acterise Zika virus infection in the placenta during different tri-
mesters17. Therefore, we used this approach to compare SARS-
CoV-2 infection between the cynomolgus and rhesus macaques.
In this case, RNAseq was used to identify and quantify mRNA in
blood samples taken longitudinally during infection. Overall, the
number of gene structures in the Ensembl genomes that used as
references for alignment, were 32,386 for the rhesus macaques
and 29,324 in cynomolgus macaques. 24,300 genes defined as one
to one orthologous in each species were used in a gene-network
analysis to compare the host response at a global level for each
species (Supplementary Fig. 3). Genes with a similar function
were clustered together into consensus modules to allow different
traits (sex of the animal and days post-infection) to be compared.
The data was also separated into consensus and opposite signs
between the cynomolgus and rhesus macaques. In general, the
consensus module showed similarity in the response to SARS-
CoV-2 between cynomolgus and rhesus macaques. For example,
the inflammatory response, biotic stimulus and interferon were
similar for both species in that the response is negatively related
to the dpc. I.e., the response occurred at the start of infection and
then wanes with length of infection. Similarly, this pattern was
seen with interferon production and response to virus for both
species. One exception was in the positive regulation of cytokine
production where the response in cynomolgus macaques had a
stronger negative response than rhesus macaques. But for both
species’ cytokine production was active at the beginning of
infection and becomes weaker at later time points. There was
some evidence of potential sex differences, although the n number
maybe too low to draw specific conclusions (Supplementary
Fig. 3).
Discussion
We have shown in a head to head comparison that the con-
sequences of challenge with SARS-CoV-2 in rhesus and cyno-
molgus macaques are similar and in line with outcomes described
in studies conducted individually in either, rhesus11,12,18,19 or
cynomolgus macaques13,20. Uniquely, our conclusion that these
two species respond similarly to SARS-CoV-2 infection, is sup-
ported by our transcriptional analysis which provides a global
view on host gene expression.
The clinical manifestations in human COVID-19 patients
range from asymptomatic to severe21–23. In our study, we have
observed that SARS-CoV-2 induced features characteristic of
COVID-19 identified on CT scans in the absence of clinical signs
in both rhesus and cynomolgus macaques. The lack of clinical
signs observed agrees with other reports that used the IN and IT
routes of challenge delivery11,13,18,20. The slightly increased levels
of clinical changes previously described in rhesus12,24,25 may be
due to the use of the ocular and oral routes in addition to IN and
IT for challenge and the potential impact of additional in-life
sampling. CT provided the only clinical measure that identified
abnormalities in vivo consistent with COVID-19 and is therefore
a critical tool for evaluation of disease burden following experi-
mental infection. Features characteristic of COVID-19 in human
patients, such as ground glass opacity and consolidation were
identified on CT scans collected from both SARS-CoV-2 chal-
lenged rhesus and cynomolgus macaques in line with reports
from studies describing SARS-CoV-2 infection in either, rhesus24,
or cynomolgus macaques20 supporting a role for both species as
models of human SARS-CoV-2 induced disease.
The pattern of viral shedding from the URT (peak day one to
three with subsequent decline to undetectable), intermittent low
recovery from the gastrointestinal tract and the absence of
detection above the LLOQ in the blood described across both
species is similar to what is observed in humans with asympto-
matic/mild COVID-19 (shedding without clinical signs and/or
after the resolution of clinical course) and reflect previous reports
of SARS-CoV-2 infection in rhesus11,12,18,19 and cynomolgus
macaques13,20. Similar to these studies, virus shed from the URT
was detected by RT-qPCR very shortly after challenge, which
could suggest the presence of residual challenge material rather
than shedding of the newly replicated virus resulting from
infection. However, subgenomic RNA was detected at these early
timepoints suggesting viral replication had indeed occurred in
both species. Similar to Rockx et al.13 and Munster et al.12 we
detected live virus, albeit at low levels in samples from the URT.
Positive samples were restricted to early timepoints post-infec-
tion-challenge, which suggests some level of new virus replication
which is also supported by the level of virus detected using RNA
probes conducted on samples collected from animals euthanised
4/5 dpc13.
Histopathological changes were comparable in both animal
species, and closely resembled that seen in human cases following
a mild/moderate clinical course26–28. Typical changes of acute
respiratory viral infection were observed, with alveolar necrosis
and type II pneumocyte hyperplasia seen on microscopy together
with interstitial lymphoid infiltrates, focally showing perivascular
cuffing. These histopathological lesions are compatible to those
observed in human patients, although some features seen in
humans, such as thromboembolic changes, were not present in
the macaques29. The pathology at 14/15 and 18/19 dpc showed
signs of resolution. We have described here a histopathology
scoring system that allows us to actually quantify the severity of
lesions in the airways and parenchyma of lung tissue sections
from SARS-CoV-2 infected macaques. We have used this system
to compare quantitatively the lung histopathology observed in
pre-clinical vaccine studies. It will also be applicable to assessing
the efficacy of therapeutics in these NHP COVID-19 models. We
have also described herein an upregulation of local interleukin-6
transcription at the mRNA level within the pulmonary lesions at
the early time points of infection in both species. The induction of
a proinflammatory cytokine storm has been described in human
COVID-19 patients, with IL-6 levels significantly elevated and
associated with the disease severity30,31.
The development of neutralising titres of specific antibodies is
important for the control of infection and viral transmission and
is a commonly reported feature in COVID-19 patients, although
neutralising antibody alone is not considered sufficient for pro-
tection against severe disease32. IgG seroconversion occurred in
both macaque species from days 8-9 post-infection and therefore
follows a similar kinetic to serology profiles measured in COVID-
19 patients33, indicating that both species offer representative
models for the investigation of SARS-CoV-2 related humoral
immunity.
In keeping with the generally mild pathology and limited evi-
dence of viral replication or persistence reported in both macaque
species, we detected little evidence in cellular immune profiles of
the immune dysregulation associated with severe COVID-19
disease in humans34. Immunological features were more typical
of those reported in milder infections and convalescent patients
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and included changes in the frequency of CD4 and CD8 T-cell
populations35 as well as increased frequencies of immunomo-
dulatory NK36 and monocyte subsets37.
The role of T-cells in SARS-CoV-2 immunity is not fully
defined, although, it is clear that CD4 and CD8 memory T-cells
are present in COVID-19 convalescent patients and those pre-
viously exposed to related coronaviruses38. CD4 T-cell dependent
mechanisms of protection have been demonstrated in small
animal models of SARS-CoV infection39, T-cells are likely to play
an important role in the development of neutralising antibodies40
and the clearance of infection through cell-mediated cytotoxi-
city32. Our findings confirm that proinflammatory and cytotoxic
T-cells are induced by SARS-CoV-2 infection in both rhesus and
cynomolgus macaques to a similar extent, and that there is T-cell
reactogenicity in both species to all three of the SARS-CoV-2
antigens included in our assays. This included the detection of
antigen-specific immune responses directed toward peptide-
epitopes spanning the S protein sequence, an antigen incorpo-
rated into several of the novel vaccine candidates currently under
investigation41, thus demonstrating the value of the macaque
model for immunogenicity testing of novel SARS-CoV-2 vaccine
candidates. Additionally, in a comparative study of colonisation
of NHPs by group A Steptococcus pyogenes it was reported that
cynomolgus developed a stronger antibody response compared to
rhesus macaques42, a trend that we also observed.
The sample size used in this study is relatively limited (6 rhesus
and 6 cynomolgus macaques), and therefore, there are limitations
to provide statistical significance for some endpoints. However,
our results clearly demonstrate that both species provide infection
models of SARS-CoV-2, which reflect upper and lower respira-
tory tract viral replication resulting in a lung injury, repair and
resolution picture typical for milder forms of COVID-19 disease
in humans. Both macaque models potentially represent the
majority of the human population and enable evaluation of the
safety and efficacy of novel and repurposed interventions against
SARS-CoV-2 using endpoints of upper and lower respiratory
tract virus replication, in addition to CT and histopathology in
the assessment of significant but transient lung injury. However,
further work is needed to develop models that are representative
of the more severe outcomes that would particularly enable the
evaluation of therapies targeting host-mediated pathology asso-
ciated with high levels of prolonged, pulmonary disease. Given
the limitations in reproducing the range of underlying health
conditions in humans that link to poorer infection outcomes (e.g.
diabetes, obesity and age) in macaques, other strategies of disease
enhancement such as challenge, route, dose, strain, or manip-
ulation of the host immunity, will be required.
The limited supply of rhesus macaques is now impacting on
future COVID-19 studies to support the development of vaccines
and therapeutic products43. The potential offered by cynomolgus
macaques as an appropriate model will greatly increase the
international community’s ability to perform these critical studies
in support of pre-clinical evaluation and product licensure.
Moreover, cynomolgus macaques with a Mauritian genotype have
more restricted genetic variability and more limited and better-
defined MHC, providing an advantage in the battle to elucidate
correlates of protective immunity. These features have been of
particular value in HIV vaccine research where models are
established in both rhesus macaques (Indian genotype) and
cynomolgus macaques (Mauritian genotype)44. The MHC
homogeneity associated with the Mauritian cynomolgus macaque
has reduced the variability between animals after vaccination and
has enhanced comparisons of vaccine regimens. In addition, the
improved consistency in outcome facilitates the use of fewer
animals to obtain statistically significant results than would be
required if more genetically diverse species were to be used.
Methods
Animals. Six cynomolgus macaques of Mauritian origin (Macaca fascicularis) and
six rhesus macaques of Indian origin (Macaca mulatta) were used in this study
(Fig. 1). Study groups comprised three males and three females of each species and
all were adults aged 2–4 years and weighing between 2.89 and 4.85 kg at time of
challenge. Before the start of the experiment, socially compatible animals were
randomly assigned to challenge groups, to minimise bias.
Animals were housed in compatible social groups, in cages in accordance with
the UK Home Office Code of Practice for the Housing and Care of Animals Bred,
Supplied or Used for Scientific Procedures (2014) and National Committee for
Refinement, Reduction and Replacement (NC3Rs) Guidelines on Primate
Accommodation, Care and Use, August 200645. Prior to challenge animals were
housed at Advisory Committee on Dangerous Pathogens (ACDP) level two in
cages approximately 2.5 M high by 4M long by 2M deep, constructed with high
level observation balconies and with a floor of deep litter to allow foraging.
Following challenge animals were transferred to ACDP Level three and housed in
banks of cages of similar construction placed in directional airflow containment
systems that allowed group housing and environmental control whilst providing a
continuous, standardised inward flow of fully conditioned fresh air identical for all
groups. Additional environmental enrichment was afforded by the provision of
toys, swings, feeding puzzles and DVDs for visual stimulation. In addition to ad
libitum access to water and standard old-world primate pellets, diet was
supplemented with a selection of fresh vegetables and fruit. All experimental work
was conducted under the authority of a UK Home Office approved project license
(PDC57C033) that had been subject to local ethical review at PHE Porton Down by
the Animal Welfare and Ethical Review Body (AWERB) and approved as required
by the Home Office Animals (Scientific Procedures) Act 1986. Animals were
sedated by intramuscular (IM) injection with ketamine hydrochloride (Ketaset,
100 mg/ml, Fort Dodge Animal Health Ltd, Southampton, UK; 10 mg/kg) for
procedures requiring removal from their housing. None of the animals had been
used previously for experimental procedures.
Viruses and Cells. SARS-CoV-2 Victoria/01/202046 was generously provided by
The Doherty Institute, Melbourne, Australia at P1 after primary growth in Vero/
hSLAM cells and subsequently passaged twice at PHE Porton in Vero/hSLAM cells
[ECACC 04091501]. Infection of cells was with ~0.0005 MOI of virus and har-
vested at day 4 by dissociation of the remaining attached cells by gentle rocking
with sterile 5 mm borosilicate beads followed by clarification by centrifugation at
1000 × g for 10 min. Whole-genome sequencing was performed, on the P3 chal-
lenge stock, using both Nanopore and Illumina as described previously47. Virus
titre of the challenge stocks was determined by plaque assay on Vero/E6 cells
[ECACC 85020206]. Cell lines were obtained from the European Collection of
Authenticated Cell Cultures (ECACC) PHE, Porton Down, UK. Cell cultures were
maintained at 37 °C in Minimum essential medium (MEM) (Life Technologies,
California, USA) supplemented with 10% foetal bovine serum (FBS) (Sigma,
Dorset, UK) and 25 mM HEPES (Life Technologies, California, USA). In addition,
Vero/hSLAM cultures were supplemented with 0.4 mg/ml of geneticin (Invitrogen)
to maintain the expression plasmid. Challenge substance dilutions were conducted
in phosphate buffer saline (PBS). Inoculum (5 × 106 PFU) was delivered by
intratracheal route (2 ml) and intranasal instillation (1.0 ml total, 0.5 ml per
nostril).
Clinical signs and in-life imaging by computerised tomography. Weight and
body temperature were monitored daily (Fig. 1). Nasal washes, throat and rectal
swabs were taken at intervals of three days for each individual, having samples
from at least two animals for each species until 5 dpc. Whole blood and serum were
collected at the same time points. Nasal washes were obtained by flushing the nasal
cavity with 2 ml PBS. For throat swabs, a flocked swab (MWE Medical Wire,
Corsham, UK) was gently stroked across the back of the pharynx in the tonsillar
area. Throat and rectal swabs were processed, and aliquots stored in viral transport
media (VTM) and AVL buffer (Qiagen, Milton Keynes, UK) at −80 °C until assay.
Animals were monitored multiple times per day for behavioural and clinical
changes. Behaviour was evaluated for contra-indicators including depression,
withdrawal from the group, aggression, changes in feeding patterns, breathing
pattern, respiration rate and cough. Prior to blood sample collection, aerosol
challenge and euthanasia, animals were weighed, examined for gross abnormalities
and body temperature measured (Fig. 1).
CT scans were performed at 18 dpc from the four remaining animals at this
time point (Fig. 1). CT imaging was performed on sedated animals using a 16 slice
Lightspeed CT scanner (General Electric Healthcare, Milwaukee, WI, USA) in the
prone and supine position to assist the differentiation of pulmonary changes at the
lung bases caused by gravity dependant atelectasis, from ground glass opacity
caused by SARS-CoV-2. All axial scans were performed at 120 KVp, with Auto mA
(ranging between 10 and 120) and were acquired using a small scan field of view.
Rotation speed was 0.8 s. Images were displayed as an 11 cm field of view. To
facilitate full examination of the cardiac and pulmonary vasculature, lymph nodes
and extrapulmonary tissues, Niopam 300 (Bracco, Milan, Italy), a non-ionic,
iodinated contrast medium, was administered intravenously (IV) at 2 ml/kg body
weight and scans were collected immediately after injection and ninety seconds
from the mid-point of injection. Scans were evaluated by an expert thoracic
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radiologist, blinded to the animal’s clinical status, for the presence of: disease
features characteristic of COVID-19 in humans (ground glass opacity (GGO),
consolidation, crazy paving, nodules, peri-lobular consolidation; distribution:
upper, middle, lower, central 2/3, bronchocentric); pulmonary embolus and the
extent of any abnormalities estimated (<25%, 25–50%, 51–75%, 76–100%).
Post-mortem examination and histopathology. Animals were euthanised at 3
different time-points, in groups of four (including one animal from each species
and sex) at 4/5, 14/15 and 18/19 dpc (Fig. 1).
Animals were anaesthetised with ketamine (17.9 mg/kg body weight) and
exsanguination was performed via cardiac puncture, followed by injection of an
anaesthetic overdose (sodium pentabarbitone Dolelethal, Vetquinol UK Ltd, 140
mg/kg) to ensure euthanasia. Post-mortem examination and sample collection
were performed immediately after confirmation of death.
The bronchial alveolar lavage fluid (BAL) was collected at necropsy from the
right lung. The left lung was dissected prior to BAL collection and used for
subsequent histopathology and virology procedures. At necropsy nasal washes,
throat and rectal swabs, whole blood and serum were taken alongside tissue
samples for histopathology.
Samples from the left cranial and left caudal lung lobe together with spleen,
kidney, liver, mediastinal and axillary lymph nodes, small intestine (duodenum,
jejunum and ileum), large intestine (caecum and colon), encephalon (cerebrum,
cerebellum and brainstem), eye, trachea, larynx and nasal cavity, were fixed by
immersion in 10% neutral-buffered formalin and processed routinely into paraffin
wax. Nasal cavity samples were decalcified using an EDTA-based solution prior to
embedding. Four µm sections were cut and stained with haematoxylin and eosin
(H&E) and examined microscopically. A lung histopathology scoring system was
setup and used to evaluate the severity of the histopathological lesions observed in
each animal (Table 1), including lesions affecting the airways and the parenchyma.
Six large tissue sections from the left lung were used to evaluate the lung
histopathology, three from the cranial lobe and three from the caudal lobe as
follows: (a) proximal to the lobar bronchus bifurcation, (b) middle portion and (c)
distal to the lobar bronchus bifurcation. Sections were analysed by two qualified
veterinary pathologists and peer-reviewed by two other qualified pathologists
(veterinary and medical).
In addition, samples were stained using the RNAscope technique to identify the
SARS-CoV-2 virus RNA or Interleukin 6 (IL-6) in lung tissue sections. Briefly,
tissues were pre-treated with hydrogen peroxide for 10 min (RT), target retrieval
for 15 min (98–102 °C) and protease plus for 30 min (40 °C) (Advanced Cell
Diagnostics). A V-nCoV2019-S probe (SARS-CoV-2 Spike gene specific), or host
species specific IL-6-S probes (Advanced Cell Diagnostics, Bio-techne) were
incubated on the tissues for 2 h at 40 °C. In addition, samples were stained using
the RNAscope technique to identify the SARS-CoV-2 virus RNA. Amplification of
the signal was carried out following the RNAscope protocol using the RNAscope
2.5 HD Detection kit—Red (Advanced Cell Diagnostics, Biotechne). Appropriate
positive and negative controls were included in each RNAscope run
(Supplementary Fig. 4)
Digital image analysis was performed in RNAscope labelled slides to ascertain
the percentage of stained cells within the lesions, by using the Nikon-NIS-Ar
package. The presence of viral RNA by ISH was evaluated using the whole lung
tissue section slides. For IL-6 mRNA, the areas of histopathological lesions were
selected as regions of interest (ROI) and the positively labelled area (red) was
calculated by the software after setting the thresholds.
Viral load quantification by RT-qPCR. RNA was isolated from nasal wash, throat
swabs, EDTA treated whole blood, BAL and tissue samples (nasal cavity, tonsil,
trachea and lung). Weighed tissue samples were homogenised and inactivated in
RLT (Qiagen) supplemented with 1%(v/v) Beta-mercaptoethanol. Tissue homo-
genate was then centrifuged through a QIAshredder homogeniser (Qiagen) and
supplemented with ethanol as per manufacturer’s instructions. Downstream
extraction was then performed using the BioSprint™96 One-For-All vet kit (Qia-
gen) and Kingfisher Flex platform as per manufacturer’s instructions. Non-tissue
samples were inactivated in AVL (Qiagen) and ethanol, with final extraction using
the QIAamp Viral RNA Minikit (Qiagen) as per manufacturer’s instructions.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was
performed using TaqPath™ 1-Step RT-qPCR Master Mix, CG (Applied
Biosystems™), 2019-nCoV CDC RUO Kit (Integrated DNA Technologies) and
7500 Fast Real-Time PCR System (Applied Biosystems™) as previously described48.
PCR amplicons were quantified against 2019-nCoV_N_Positive Control
(Integrated DNA Technologies). Positive samples detected below the lower limit of
quantification (LLOQ) of 20 copies/µl were assigned the value of 13 copies/µl,
undetected samples were assigned the value of ≤6.2 copies/µl, equivalent to the
assays LLOD. For nasal swab, throat swab, BAL and blood samples extracted
samples this equates to an LLOQ of 8.57 × 103 copies/ml and LLOD of 2.66 × 103
copies/ml.
Subgenomic RT-qPCR. Subgenomic RT-qPCR was performed on the Quant-
Studio™ 7 Flex Real-Time PCR System using TaqMan™ Fast Virus 1-Step Master
Mix (Thermo Fisher Scientific) and oligonucleotides as specified by Wolfel et al.,
with forward primer, probe and reverse primer at a final concentration of 250 nM,
125 nM and 500 nM respectively. Sequences of the sgE primers and probe were:
2019-nCoV_sgE-forward, 5′ CGATCTCTTGTAGATCTGTTCTC 3′; 2019-
nCoV_sgE-reverse, 5′ ATATTGCAGCAGTACGCACACA 3′; 2019-nCoV_sgE-
probe, 5′ FAM- ACACTAGCCATCCTTACTGCGCTTCG-BHQ1 3′. Cycling
conditions were 50 °C for 10min, 95 °C for 2 min, followed by 45 cycles of 95 °C for
10 s and 60 °C for 30 s. RT-qPCR amplicons were quantified against an in vitro
transcribed RNA standard of the full-length SARS-CoV-2 E ORF (accession number
NC_045512.2) preceded by the UTR leader sequence and putative E gene tran-
scription regulatory sequence described by Wolfel et al. in 202049. Positive samples
detected below the lower limit of quantification (LLOQ) were assigned the value of 5
copies/µl, whilst undetected samples were assigned the value of ≤0.9 copies/µl,
equivalent to the assays lower limit of detection (LLOD). For nasal swab, throat
swab, BAL and blood samples extracted samples this equates to an LLOQ of 1.29 ×
104 copies/mL and LLOD of 1.16 × 103 copies/mL For tissue samples this equates to
an LLOQ of 5.71 × 104 copies/g and LLOD of 5.14 × 103 copies/g. Sequences of
primers and probes are included in Supplementary Table 1.
Plaque assay. Samples were incubated in 24-well plates (Nunc, ThermoFisher
Scientific, Loughborough, UK) containing twice washed with Dulbecco’s PBS
(DPBS) monolayers of Vero E6 cells seeded the previous day at 1.5 × 105 cells/well
under Overlay media consisting of MEM (Life Technologies) containing 1.5%
carboxymethylcellulose (Sigma), 4% (v/v) heat-inactivated foetal calf serum (FCS)
(Sigma) and 25 mM HEPES buffer (Gibco). After incubation at 37 °C for 120 h,
they were fixed overnight with 10% (w/v) formalin/PBS, washed with tap water and
stained with methyl crystal violet solution (0.2% v/v in 40% (v/v) Ethanol) (Sigma).
Plaque reduction neutralisation test. Neutralising virus titres were measured in
heat-inactivated (56 °C for 30 min) serum samples. SARS-CoV-2 was diluted to a
concentration of 1.4 × 103 pfu/ml (70 pfu/50 µl) and mixed 50:50 in 1% FCS/MEM
with doubling serum dilutions from 1:10 to 1:320 in a 96-well V-bottomed plate.
The plate was incubated at 37 °C in a humidified box for 1 h to allow the antibody
in the serum samples to neutralise the virus. The neutralised virus was transferred
into the wells of a washed plaque assay 24-well plate (see plaque assay method),
allowed to adsorb at 37 °C for a further hour, and overlaid with plaque assay
overlay media. After 5 days incubation at 37 °C in a humified box, the plates were
fixed, stained and plaques counted.
A mid-point probit analysis was used to determine the dilution of antibody
required to reduce SARS-CoV-2 viral plaques by 50% (PRNT50) compared with
the virus only control (n= 5). Analysis was conducted in R50 and the script was
based on a source script from Johnson et al. 51.
ELISA. A full-length trimeric and stabilised version of the SARS-CoV-2 Spike
protein (amino acids 1-1280, GenBank: MN MN908947) was developed and kindly
provided by Florian Krammer’s lab as previously described52. Recombinant SARS-
CoV-2 Receptor-Binding-Domain (319-541) Myc-His was developed and kindly
provided by MassBiologics, USA. Recombinant SARS-CoV-2 Nucleocapsid phos-
phoprotein (GenBank: MN908947, isolate Wuhan-Hu-1) was expressed and pur-
ified from Escherichia coli as full-length nucleoprotein (amino acids 1-419) with a
C-terminal 6xHis-Tag (REC31812-100, Batch #20042310, Native Antigen
Company).
Spike-, Spike RBD- and NP-specific IgG responses were determined by ELISA.
High-binding 96-well plates (Nunc Maxisorp) were coated with 50 µl per well of 2
µg/ml Spike trimer, Spike RBD or NP in 1X PBS (Gibco) and incubated overnight
at 4 °C. The ELISA plates were washed five times with wash buffer (1 X PBS/0.05%
Tween 20 (Sigma)) and blocked with 100 µl/well 5% FBS (Sigma) in 1 X PBS/0.1%
Tween 20 for 1 h at room temperature. After washing, serum samples previously
0.5% Triton-inactivated were serially diluted in 10% FBS in 1 X PBS/0.1% Tween
20, 50 µl/well of each dilution were added to the antigen coated plate and incubated
for 2 h at room temperature. Following washing, anti-monkey IgG conjugated to
HRP (Invitrogen) were diluted (1:10,000) in 10% FBS in 1 X PBS/0.1% Tween 20
and 100 µl/well were added to the plate, then incubated for 1 h at room
temperature. After washing, 1 mg/ml O-phenylenediamine dihydrochloride
solution (Sigma) was prepared and 100 µl per well were added. The development
was stopped with 50 µl per well 1 M Hydrochloric acid (Fisher Chemical, J/4320/
15) and the absorbance at 490 nm was read using Softmax 7.0. Endpoint titres and
statistical analyses (Kruskal–Wallis one-way ANOVA) were performed with Graph
Pad Prism 8.0. The cut-off was set at the average Optical Density of samples
collected from naïve animals (Day 0) + 3 Standard Deviation.
Mononuclear cell Isolation. PBMCs were isolated from whole blood antic-
oagulated with heparin (132 Units per 8 ml blood) (BD Biosciences, Oxford, UK)
using standard methods. Of note is that the material used for density gradient
centrifugation was adjusted dependent on the macaque species, with a Ficoll
Histopaque gradient (GE Healthcare, USA) used with rhesus macaque blood and a
Percoll gradient (GE Healthcare) used with cynomolgus macaques. Mononuclear
cells (MNC) were isolated from spleen and lung tissue samples using an Octo-
MACS tissue dissociation device (Miltenyi Biotec). Lung tissue samples were dis-
sected into approximately 5mm3 pieces and incubated for 1 h in a solution of 772.8
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U/ml collagenase + 426 U/ml DNase (both from Sigma) diluted in Earle’s balanced
salt solution supplemented with 200 mg/ml Calcium Chloride (Gibco, Life Tech-
nologies, Renfrew, UK), at 37 °C with continual gentle mixing of the tube. The
homogenised solution was passed through a 70 µm cell filter (BD Biosciences) and
the mononuclear cells separated by Ficoll Histopaque density gradient cen-
trifugation. PBMCs and MNC isolated from tissues were stored at −180 °C until
resuscitated for analysis.
Resuscitation of cryopreserved cells. PBMCs and MNC were thawed, washed in
R10 medium (consisting of RPMI 1640 supplemented with 2 mM L-glutamine, 50
U/ml penicillin- 50 μg/ml streptomycin, and 10% heat-inactivated FBS) with 1 U/
ml of DNase (Sigma), and resuspended in R10 medium and incubated at 37 °C 5%
CO2 overnight.
ELISPOT. An IFNγ ELISpot assay was used to estimate the frequency and IFNγ
production capacity of SARS-CoV-2-specific T-cells in PBMCs using a human/
simian IFNγ kit (MabTech, Nacka. Sweden), as described previously53. The cells
were assayed at 2 × 105 cells per well, unless there were not enough cells, in which
case 1 × 105 cells were used. Cells were stimulated overnight with SARS-CoV-2
peptide pools and ‘megapools’ of the spike protein (Mimotopes, Australia). Ten
peptide pools were used, comprising of 15mer peptides, overlapping by 11 amino
acids and offset by 4 amino acids. Peptides were resuspended in 10% DMSO to a
median concentration of 9.22 mg/ml. Peptides were then pooled and aliquoted.
Before use peptides were resuspended to a concentration of 5 µg/peptide in media,
they were then loaded onto the ELISpot plate, 50 µl/well. This peptide library is
based on GenBank: MN908947.3 sequence. Full sequences of peptides are included
in Supplementary Table 2. The three megapools were made up as such: Megapool 1
(MP1) comprised peptide pools 1-3, Megapool 2 (MP2) comprised peptide pools 4-
6 and Megapool 3 (MP3) comprised of peptide pools 7-10. All peptides were used
at a concentration of 1.7 µg per well. Phorbol 12-myristate (Sigma) (100 ng/ml) and
ionomycin (CN Biosciences, Nottingham, UK) (1 mg/ml) were used as a positive
control. Results were calculated to report as spot forming units (SFU) per million
cells. All SARS-CoV-2 peptides and megapools were assayed in duplicate and
media only wells subtracted to give the antigen-specific SFU. ELISPOT plates were
analysed using the CTL scanner and software (CTL, Germany) and further analysis
carried out using GraphPad Prism (version 8.0.1) (GraphPad Software, USA)
Immunophenotyping and Intracellular cytokine staining assays. Naïve animal
samples were taken from previous studies.
Intracellular cytokine staining (ICS) and immunophenotyping assays were
performed using 1 × 106 PBMC or MNC in R10 medium (described above). For
intracellular cytokine staining, these cells were stimulated with a 10 μg/ml solution
of CD28 and CD49d co-stimulatory antibodies (both from BD Biosciences) and
1ug/ml of 15-mer overlapping peptide pools spanning either the SARS-CoV-2
spike (S), nucleocapsid (N) or membrane glycoprotein (M) sequence (Miltenyi
Biotec, Bisley, UK) or 5 μg/ml staphylococcal enterotoxin b (SEB) (Sigma), or R10
medium with matched concentration of DMSO as negative control, for a total of
16 h at 37 °C, in a 5% CO2 supplemented incubator. Anti-CD107a-AF488 (BD
Biosciences) was included during cell stimulations. Following the initial 2 h of
incubation, the protein transport inhibitor Brefeldin-A (Sigma) was added at a final
concentration of 10 μg/ml. Following incubation, cells were washed with FACS
buffer consisting of PBS+ 1% FCS and incubated for 30 min at room temperature
with optimal dilutions of the amine-reactive Live/Dead Fixable Red viability cell
stain (Life Technologies) and the antibodies CD4 PerCP-Cy5.5, CD8 APC-Fire750,
CD69-BV510, (all from BD Biosciences) and CD20- Pe-Dazzle-594, γδ-TCR-
BV421 (Biolegend, London, UK) prepared in BD Biosciences Brilliant stain buffer
(BD Biosciences, Oxford, UK). Following surface marker staining, the cells were
washed and then permeabilised by incubation at room temperature for 15 min with
Fix/Perm reagent (BD Biosciences) before washing with Permwash buffer (BD
Biosciences). Intracellular antigen staining was applied by incubation at room
temperature for 30 min with the antibodies CD3-AF700, IFN-γ-PeCy7, TNF-α-
BUV395, GM-SCF-PE (all from BD Biosciences, Oxford, United Kingdom), IL-2-
APC (Miltenyi Biotech Ltd), IL-17-BV711 (Biolegend, London, UK) prepared in
brilliant stain buffer. For immunophenotyping assays, cells were washed with FACs
buffer by centrifugation before staining with amine-reactive Live/Dead Fixable
violet viability cell stain as per the manufacturer’s instructions (Life Technologies).
Table 1 Pulmonary histopathology scoring system.
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Cells were then incubated for 30 min at room temperature with optimal dilutions
of the following antibodies: anti-CD4-PerCP-Cy5.5, anti-CD8-APC-Fire750 anti-
CD11c-PE. anti-CD14-APC, anti-CD16-BV786, anti-CD20-PE-Dazzle (all from
BioLegend); anti-CD3-AF700, anti-CD56-BV605, anti-HLA-DR-BUV395 (all from
BD Biosciences); anti-CD159a-PC7 (Beckman Coulter) prepared in brilliant stain
buffer. BD Compbeads (BD Biosciences) were labelled with the above
fluorochromes for use as compensation controls. Following antibody labelling, cells
and beads were washed by centrifugation and fixed in 4% paraformaldehyde
solution (Sigma) prior to flow cytometric acquisition.
Flow cytometric acquisition and analysis. Cells were analysed using a five laser
LSRII Fortessa instrument (BD Biosciences) and data were analysed using FlowJo
(version 9.7.6, BD Biosciences). Cytokine-producing T-cells were identified using a
forward scatter-height (FSC-H) versus side scatter-area (SSC-A) dot plot to identify
the lymphocyte population, to which appropriate gating strategies were applied to
exclude doublet events, non-viable cells and B cells (CD20+). For ICS analysis,
sequential gating through CD3+, followed by CD4+ or CD8+ gates were used
before individual cytokine gates to identify IFN-γ, IL-2, TNF-α, GM-CSF and IL-
17, CD107a and CD69 stained populations. In immunophenotyping datasets,
classical-, non-classical-monocytes and monocyte derived dendritic cells (mDCs)
were identified by FSC and SSC characteristics and by the expression pattern of
HLA-DR, CD14, CD16 and CD11c within the live CD3-, CD20- population.
Similarly, natural killer cells subsets were identified by expression of CD8, CD159a,
CD56 and CD16 within live CD3- lymphocyte subsets. Polyfunctional cells were
identified using Boolean gating combinations of individual cytokine-producing
CD4 or CD8 T-cells. The software package PESTLE version 1.7 (Mario Roederer,
Vaccine Research Centre, NIAID, NIH) was used for background subtraction to
obtain antigen-specific polyfunctional ICS cytokine responses, Graphpad Prism
(version 8.0.1) was used to generate graphical representations of flow cytometry
data. Gating strategy for flow cytometry analyses are summarised in Supplementary
Figs. 5, 6.
Sequencing, data collection and data deposition. Total RNA was extracted from
whole blood with the QIAmp viral RNA extraction kit and eluted in pure water.
Following the manufacture’s protocols, total RNA was used as input material into
the QIAseq FastSelect–rRNA HMR (Qiagen) protocol to remove cytoplasmic and
mitochondrial rRNA with a fragmentation time of 7 or 15 min. Subsequently, the
NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina® (New England
Biolabs) was used to generate the RNA libraries, followed by 11 or 13 cycles of
amplification and purification using AMPure XP beads. Each library was quantified
using Qubit and the size distribution assessed using the Agilent 2100 Bioanalyser
and the final libraries were pooled in equimolar ratios. The raw fastq files (2 ×150
bp) generated by an Illumina® NovaSeq 6000 (Illumina®, San Diego, USA) were
trimmed to remove Illumina adapter sequences using Cutadapt v1.2.154. The
option “−O 3” was set, so the that 3’ end of any reads which matched the adapter
sequence with greater than 3 bp was trimmed off. The reads were further trimmed
to remove low quality bases, using Sickle v1.20055 with a minimum window quality
score of 20. After trimming, reads shorter than 10 bp were removed. Sequence
reads that mapped to Macaca mulatta or Macaca fascicularis are deposited under
NCBI bioproject: PRJNA681111.
Bioinformatic Analysis. Hisat2 v2.1.056 was used to map the trimmed reads on the
Macaca mulatta or Macaca fascicularis reference host genome assemblies (release-
94) downloaded from the Ensembl FTP site. The resultant Sam files were processed
by featureCounts v2.0.057 with the default setting to generate raw read counts per
gene. One-to-one orthologs were defined as the orthologous genes of M. mulatta
and M. fascicularis in Ensembl (release-94) with reciprocally highest homologue
ortholog confidence. For comparison between the two species, 24,300 one-to-one
orthologs with their raw read counts were used for analysis. For the gene-network
analysis on the blood samples, first low-expression genes (at least 1 read per million
in 1 of the samples) were filtered and gene counts in the Macaca sp. datasets were
normalised and log-transformed with the command rpkm() in EdgeR58. Then 25
Consensus modules in M.mulatta and M. fascicularis were derived from
WGCNA59 with blockwiseConsensusModules function (power= 8, TOMType
= “signed”, corType= “bicor”, maxPOutliers=0.05, minModuleSize=30, deepSplit
= 4). Species specific modules were identified by relating consensus modules to the
M. mulatta modules and M. fascicularis modules. The GO enrichment analysis for
differentially expressed genes and modules were performed using clusterProfiler60.
The module function was identified by dual enrichment.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data and materials used in the analysis are presented in the main manuscript and
supplementary information files. Accession number PRJNA681111 is available at https://
www.ncbi.nlm.nih.gov/bioproject/PRJNA681111 Source data are provided with
this paper.
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